Trial
NCT04435717
Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01)
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Hospital Universitario Ramon y Cajal
Collaborators
—
Condition
Covid19
Intervention
Tocilizumab 20 MG/ML Intravenous Solution [ACTEMRA]_#1
Why stopped
Futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-08-30